Panoramica dell'azienda
Evolent Health, Inc. operates through its subsidiary to deliver specialty care management services within the oncology, cardiology, and musculoskeletal sectors across the United States, while also offering an integrated value-based care platform for health plan administration. The enterprise functions within the Healthcare sector, specifically classified under the Health Information Services industry, positioning it as a specialized intermediary focused on administrative and clinical management rather than direct patient care delivery. On a scale that defines its current market presence, the company boasts a market capitalization of $260.12M and generates total annual revenue of $1.88B, supported by a workforce of 4200 employees. These valuation and revenue figures indicate that Evolent Health maintains a significant operational footprint in the health information services landscape, yet its relatively modest market cap relative to its substantial revenue base suggests a specific market dynamic or investor perception regarding future profitability that warrants detailed examination of its financial structure.
Salute finanziaria
The company reported revenue of $1.88B over the trailing twelve months, yet recorded a net income of -$579,401,024, revealing a substantial gap between top-line activity and bottom-line profitability that points to a highly leveraged cost structure or significant one-time charges impacting the bottom line. Despite the negative net income, the business generated an EBITDA of $88.22M, indicating that operational cash generation before financing costs and taxes remains positive even while reported earnings are suppressed. The firm demonstrated strong financial flexibility with free cash flow of $98.41M, a metric that highlights the ability to generate cash from operations sufficient to cover capital expenditures and potentially fund future initiatives despite the accounting losses. The margin profile presents a complex picture: a gross margin of 21.3% suggests moderate pricing power or cost control in direct service delivery, while an operating margin of -2.1% and a profit margin of -28.5% indicate that general and administrative expenses, combined with the aforementioned net loss, are eroding profitability at a significant rate. Liquidity and solvency analysis shows the company holds cash of $151.86M against total debt of $989.70M, resulting in a debt-to-equity ratio of 238.37, which characterizes a highly leveraged balance sheet where debt obligations significantly exceed equity capitalization. Short-term liquidity is supported by a current ratio of 1.31, suggesting the company possesses sufficient current assets to cover current liabilities, though the margin of safety is moderate given the high leverage. Returns on invested capital are negative, with a return on equity of -66.5% and a return on assets of -0.1%, metrics that collectively reveal management has not yet achieved positive returns on the capital deployed, reflecting the current financial distress or high investment phase of the business model.
Valutazione del valore
Valuation multiples for Evolent Health show a trailing P/E ratio of N/A due to the negative earnings, whereas the forward P/E stands at 5.27, implying that the market is pricing the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 0.63, indicating that the stock trades at a discount to its book value, which typically suggests the market perceives the company as undervalued relative to its assets or anticipates significant future losses that will further erode book value. Alternative valuation metrics such as the price-to-sales ratio of 0.14 and the EV/EBITDA of 12.45 provide additional context, suggesting the company is valued very cheaply relative to its sales volume and enterprise value to earnings before interest and taxes. The stock's price volatility is contained within a 52-week range bounded by a high of $12.06 and a low of $2.10, meaning the current price sits significantly below the recent peak, specifically trading at 82.4% below the 52-week high if calculated from the low, or simply residing in the lower portion of the observed trading band. The beta value of 0.37 indicates that the stock exhibits low price volatility relative to the broader market, moving with less intensity than the overall market index, which offers a degree of defensive characteristics despite the underlying financial challenges.
Growth & Income
Revenue growth year-over-year stands at -27.5%, while earnings growth is N/A due to the lack of positive prior-year earnings to compare against, meaning the traditional analysis of whether earnings are growing faster or slower than revenue is not applicable in the standard sense. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flows are being retained within the company rather than distributed to shareholders. This retention strategy aligns with the necessity to service its heavy debt load and potentially invest in operations to reverse the negative trends seen in revenue and profitability. Consequently, the overall growth and income profile is defined by a contraction in top-line revenue and a complete absence of income distribution to investors, reflecting a capital-intensive phase where the company prioritizes balance sheet restructuring and operational stabilization over shareholder returns or top-line expansion.